Coronavirus Live Count Map India
remove_red_eye 889 Views
COVID-19 Vaccine Updates
#Business And Medicine #Emergency Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
AstraZeneca has initiated the late-stage clinical trials of an experimental long-acting monoclonal antibody combination drug, which the company hopes could be a prophylactic to prevent COVID-19 infection in at-risk individuals for up to 12 months.
The Phase III international clinical trial is going to recruit 5,000 individuals across Europe and the United States to determine the safety and effectiveness of the antibody cocktail, known as AZD7442. The prophylactic treatment introduces antibodies, rather than inciting the body’s immune system to make them. The treatment may prove useful in individuals whose immune systems are weaker or compromised, and those who donot respond to vaccination. The trials of the monoclonal antibody combination started on Saturday in Britain, and will recruit 1,000 participants at nine sites… (Reuters, November 21, 2020)